Circulating Tumor DNA, Tissue Sequencing Have Complementary Value, Suggests UCSD-led Clinical Study | GenomeWeb

NEW YORK (GenomeWeb) – Researchers from the University of California, San Diego have confirmed that testing circulating tumor DNA from cancer patients in a clinical setting can uncover actionable mutations and guide therapy, but also that tissue sequencing and liquid biopsy have unique and likely complementary value.

Though these types of studies have become ubiquitous in the realm of tissue-based next-generation sequencing, medical centers are still in the early days of tracking the results of clinically implemented liquid biopsy tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.

Sponsored by

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.